Evidence map›Paper›PMID 41925980›Full record

ReviewDiscover nano2026

Advances in methotrexate nano-formulations to enhance therapeutic efficacy against drug-resistant breast cancer.

Satyajit Tripathy, Barsha Dassarma, Bhavna Jha, Mohd Ashif Azad, Ishita Saha, Pragati Gupta, Devlina Das Pramanik, Kunzang Chosdol, Arindam Pramanik

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Satyajit Tripathy *Amity Institute of Health Allied Science, Amity University, Noida, Uttar Pradesh, 201301, India.
Barsha Dassarma *Amity Institute of Health Allied Science, Amity University, Noida, Uttar Pradesh, 201301, India.
Bhavna JhaAmity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, 201301, India.
Mohd Ashif AzadAmity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, 201301, India.
Ishita SahaMayo Clinic Florida, 4500 San Pablo Rd S, Jacksonville, Fl, 32224-1865, USA.
Pragati GuptaAmity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, 201301, India.
Devlina Das PramanikAmity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, 201301, India.
Kunzang ChosdolDepartment of Biochemistry, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029, India.
Arindam PramanikAmity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, 201301, India. arindampramanik87@gmail.com.

Funding

Indian Council of Medical Research EMDR/SG/15/2024-01-00616
6 · The paper itself

Abstract

Methotrexate (MTX), a widely used chemotherapeutic agent and folate antagonist, is commonly employed in the treatment of various cancers and immune-mediated inflammatory diseases. However, conventional MTX therapy is associated with several limitations, including intestinal mucositis, high systemic toxicity, low bioavailability, poor pharmacokinetics, and a short half-life. To overcome these drawbacks, recent advances have focused on encapsulating MTX within nanoparticles (NPs) or polymer-based systems, which enhance sustained drug release, reduce toxicity and improve therapeutic efficacy. This review highlights various MTX-based nano-delivery systems developed for breast cancer treatment, including gold NPs, mesoporous silica NPs, lipid–polymer hybrid NPs, chitosan NPs, magnetic alginate NPs, iron oxide magnetic NPs, and carbon nanotubes. Preclinical studies on targeted delivery approach utilizing these nanocarriers has demonstrated reduced systemic toxicity and improved treatment outcomes in breast cancer models. This highlights the need for more research focused on clinical trials and combination therapies to further enhance therapeutic benefits.

Indexed as

Breast cancerMethotrexateMethotrexate nanoconjugateMultidrug resistanceNano-delivery systems

Identifiers

PMID41925980
PMCPMC13046928

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.